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Oestrogen deficiency modulates particle-induced
osteolysis
Christophe Nich1*, Jean Langlois1, Arnaud Marchadier2,3, Catherine Vidal3, Martine Cohen-Solal4, Hervé Petite1 and
Moussa Hamadouche1
Abstract
Introduction: Postmenopausal osteoporosis may modulate bone response to wear debris. In this article, we
evaluate the influence of oestrogen deficiency on experimental particle-induced osteolysis.
Methods: Polyethylene (PE) particles were implanted onto the calvaria of normal controls, sham-ovariectomized
(OVX), OVX mice and OVX mice supplemented with oestrogen (OVX+E). After 14 days, seven skulls per group were
analyzed using a high-resolution micro-computed tomography (micro-CT) and histomorphometry, and for tartrate-
specific alkaline phosphatase. Five calvariae per group were cultured for the assay of IL-1b, IL-6, TNF-a and receptor
activator of the nuclear factor B (RANKL) secretion using quantitative ELISA. Serum IL-6 concentrations were
obtained. The expression of RANKL and osteoprotegerin (OPG) mRNA were evaluated using real-time PCR.
Results: As assessed by μCT and by histomorphometry, PE particles induced extensive bone resorption and an
intense inflammatory reaction in normal controls, sham-OVX and OVX+E mice, but not in the OVX mice group. In
normal controls, sham-OVX and OVX+E mice, PE particles induced an increase in serum IL-6, in TNF-a and RANKL
local concentrations, and resulted in a significant increase in RANKL/OPG messenger RNA (mRNA) ratio. Conversely,
these parameters remained unchanged in OVX mice after PE implantation.
Conclusions: Oestrogen privation in the osteolysis murine model ultimately attenuated osteolytic response to PE
particles, suggesting a protective effect. This paradoxical phenomenon was associated with a down-regulation of
pro-resorptive cytokines. It is hypothesized that excessive inflammatory response was controlled, illustrated by the
absence of increase of serum IL-6 in OVX mice after PE implantation.
Introduction
Aseptic loosening of total joint replacements develops as
a consequence of periprosthetic osteolysis, caused by a
macrophage-mediated inflammatory reaction [1,2].
Although it is well established that generation of poly-
ethylene (PE) particles by the bearing couple is corre-
lated with the risk for revision due to aseptic loosening
[3], great variations in the degree of osteolysis are some-
times observed in clinical practice. This suggests that
patient-related factors cause variability in the host
response to PE particles. Authors have reported various
factors, such as genetically determined obesity [4], and
genetic background [5], as potential candidates involved
in the modulation of host response to PE particles. In a
recent work, we evaluated the bone response to particu-
late debris in an ovariectomized mice model [6]. We
hypothesized that high bone turnover driven by oestro-
gen deficiency following ovariectomy would result in
accelerated bone loss in the area in contact with the PE
particles. Paradoxically, particle-induced osteolysis was
found significantly decreased in this model, indicating
that ovariectomy could be protective against wear deb-
ris-induced osteolysis, possibly via sex steroid hormone
deficiency. Particle-induced osteolysis has been shown
to follow a biologic pathway, driven by cytokines such
as interleukin (IL)-1b, IL-6, and tumor necrosis factor
(TNF)-a. These mediators have been found in the soft
tissue of joints with loosened prostheses [7] and appear
to be released by human macrophage or macrophagelike
cells in vitro [8]. There is evidence that the RANK
(receptor activator of the nuclear factor B)/RANKL
(RANK ligand) system acts downstream from IL-1, IL-6
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and TNF-a and may be the ultimate effector mediating
the effects of cytokines on the regulation of bone
resorption [9]. Ovariectomy has been shown to decrease
bone mass, stimulate bone remodeling, and increase IL-
6 levels in bone marrow [10,11], and to produce an
osteoporotic bone phenotype, similar to postmenopausal
osteoporosis. Interestingly, high levels of the three
above-mentioned cytokins have been found in bone
deprived of oestrogen [12].
Although the osteoprotective action of oestrogen is
demonstrable in rodents, its implication in particle-
induced osteolysis has never been shown. The purpose
of the present study was to investigate the influence of
oestrogen on the mechanism underlying particle-
induced osteolysis in the murine calvaria model. Follow-
ing our previous findings, we primarily hypothesized
that oestrogen supplementation in ovariectomized mice
would restore an extensive bone response to PE parti-
cles. In an attempt to shed light on possible underlying
regulation, we secondly evaluated the local implication
of the RANK/RANKL/OPG system and IL-1b, IL-6,
TNF-a cytokins.
Materials and methods
Particles
Pure polyethylene particles (Ceridust VP 3620) were
obtained from Clariant (Gersthofen, Germany). In our
hands, the particle size was determined using scanning
electron microscopy as previously detailed [6]. The
mean particle size was 5.14 μm ± 3.05 μm (median 4.39
μm; range 0.52 to 15.5 μm). More than 55% of the parti-
cles were less than 5 μm in size. All particles were
washed in ethanol to remove endotoxins, and then dried
in a dessicator [6]. This treatment resulted in negative
testing for endotoxins using a quantitative Limulus
Amebocyte Lysate (LAL) Assay (Charles River, Margate,
UK) at a detection level of <0.05 EU/mL. Particles were
stored at 4°C before implantation.
Animal surgery and experimental protocol
Eleven week-old C57BL/6J female mice (n = 96) were
purchased from Janvier Laboratory (Le Genest-Saint-
Isle, France). All mice were handled in agreement with
French and international guidelines for care and use of
laboratory animals. The protocol was given ethical
approval by the local Animal Care Committee. Forty-
eight mice were subjected to bilateral ovariectomy
(OVX group) via the dorsal approach under general
anesthesia (isoflurane). Twenty-four mice were sham-
ovariectomized (sham-OVX), that is, ovaries were exter-
iorized, but not removed. Twenty-four non-OVX mice
constituted the normal control group. Animals were
housed in quarantine under local vivarium conditions
(24°C and 12 h/12 h light/dark cycle) for one week.
Surgical implantation of PE particles has been pre-
viously described [4]. Briefly, mice were operated on
under general anesthesia via inhaled isoflurane. All ani-
mals were 12 weeks old at surgery. A 0.5 × 0.5 cm2 area
of periostum was exposed by making a 10 mm midline
sagittal incision over the calvaria. In PE-implanted
groups, the particle powder (20 μg) was distributed uni-
formly over the intact periosteum using a sterile sharp
surgical spoon. Table 1 shows the treatment of the dif-
ferent experimental groups of mice. Postoperatively, 24
OVX animals, including 12 sham-implanted mice and
12 mice implanted with particles, were given subcuta-
neous oestrogen replacement therapy five days per week
(15 μg 17 beta-estradiol/kg body weight/day, Sigma Inc.,
St. Louis, MO, USA), and 24 OVX animals, including 12
sham-implanted mice and 12 mice implanted with parti-
cles, received subcutaneous vehicle only. Water and
food were given ad libitum. Body weights were mea-
sured weekly, and the E injections were adjusted accord-
ingly. Fourteen days postoperatively, the animals were
sacrificed by an overdose of intraperitoneal sodium pen-
tobarbital. The uteri were harvested and weighted to
confirm oestrogen loss.
Micro-computed tomography imaging and volumetric
osteolysis analysis
Seven calvariae per group were dissected after sacrifice.
Specimens were freed of all soft tissues, and fixed in
4% neutralized paraformaldehyde. The skulls were ana-
lyzed with a high-resolution micro-computed tomo-
graph (micro-CT) (Skyscan 1172; Skyscan, Aartselaar,
Belgium) to perform qualitative and quantitative ana-
lyses of calvarial bone. Imaging analysis mainly focused
on the osseous properties in the area of the skull sagit-
tal suture. The radiographic projections (n = 210) were
acquired at 80 kV and 100 μA with an exposure time
Table 1 Experimental mice groups
Normal control group Sham-OVX group OVX group Total (n)
OVX + Vehicle OVX+E
PE (-) 12 12 12 12 48
PE (+) 12 12 12 12 48
Total (n) 24 24 24 24 96
E, oestrogen; PE(-), sham-implanted; PE(+), PE-implanted; OVX, ovariectomy.
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of 100 ms. Eight frames were averaged for each rota-
tion increment of 0.9° to increase the signal to noise
ratio. 3D images were reconstructed with a voxel aver-
age size of 10 μm, using the manufacturer reconstruc-
tion software (NRecon, Skyscan). Qualitative and
quantitative data were analyzed with a global fixed
threshold [13]. To minimize the bias from the 3D
orientation of the calvaria, a spheric volume of interest
(VOI of 2 mm diameter) with the midline suture of
the skull in its center was defined, as previously
described [6]. For quantitative analysis of PE particle-
induced osteolysis, the resident software (CTAn, Sky-
scan) was used to obtain the following measurements
within the VOI: bone volume (BV, mm3), and trabecu-
lar thickness (Tb.Th., mm). To address bone tissue
mineralization following oestrogen depletion/substitu-
tion, a relative density measurement was computed.
For this purpose, the mean value of grey-level inten-
sity, reflecting the density of bone tissue, was obtained
in entire calvariae.
Histologic evaluation of osteolysis
Calvariae were processed undecalcified after embedding
in polymethyl-methacrylate according to a method pre-
viously described [6]. Sections (10 μm) were obtained at
the depth where the presence of particles was detected
within the calvaria tissue. These sections were stained
with Stevenel Blue and picrofuchsine and a serial section
stained for tartrate-specific acid phosphatase-positive
(TRAP) osteoclasts (Acid Phosphatase kit, Sigma-
Aldrich, Steinheim, Germany). Using a magnification of
20×, the histomorphometric analysis of each calvaria cap
was performed on the most central section and on four
adjacent sections. The region of interest was defined as
previously recommended [4]. The sagittal suture area
(SSA) was determined by tracing the area of soft tissue
between the parietal bones. It included resorption pits
on the superior surface of the calvaria visible in the
same field as the midline suture. To determine bone
thickness, sections were divided using a digital caliper in
four 100 μm steps to the left and right sides of the mid-
line suture respectively. The measurements were
expressed as a percentage of the mean ratio of bone
thickness to the total tissue thickness (BT/TT) of the
nine regional measurements in the five adjacent sec-
tions. To quantify bone loss, results were also expressed
as a percentage of the mean difference of BT/TT (Δ
(BT/TT)) between sham-operated and particle-
implanted animals, in normal controls, sham-OVX,
OVX, and OVX + E mice groups. Osteoclasts were
identified as large multinucleated cells located on the
bone perimeter within a resorption lacuna. Their locali-
zation was confirmed in a serial section stained for tar-
trate-specific acid phosphatase. The osteoclast number
was measured in the region of interest of the five conse-
cutive calvaria sections.
Calvariae culture
Calvariae were removed en bloc under sterile conditions
from five animals per group randomly assigned for cul-
ture. Each calvaria was placed into one well of 12 wells/
plate and cultured with 1 ml serum-and phenol-free
Dulbecco’s modified Eagle’s medium (DMEM) with glu-
tamine (Invitrogen, Paisley, UK), and 1% penicillin and
streptomycin at 37°C and 5% CO2 for 24 h. Twenty
four hours later, the culture medium was collected and
stored at -80°C for the assay of IL-1b, IL-6, TNF-a and
RANKL secretion. Then, calvariae were calcinated and
ashes weighted to normalize the production of
cytokines.
ELISA for IL-1b, IL-6, TNF-a and RANKL detection
To measure IL-6 concentration in serum, blood was
obtained by cardiac puncture before death, and collected
in heparinized tubes. Blood samples were then centri-
fuged at 3,000 × g for 10 minutes, aliquoted and frozen
at -80°C until assayed. Serum measurements of IL-6
were performed using quantitative, noncompetitive,
sandwich enzyme-linked immunosorbent assay kit for
detecting mouse IL-6 (Quantikine, R&D Systems Eur-
ope, Ltd, Abingdon, UK). Similarly, ELISA kits for
detecting mouse IL-6, IL-1b, TNF-a and RANKL (R&D
Systems) were employed to measure cytokines released
into organ culture supernatant. The detection limits of
the assay were 1.6 pg/mL for IL-6, 3 pg/mL for IL-1b,
5.1 pg/mL for TNF-a, and 5 pg/mL for RANKL. Cyto-
kines levels lower than the detection limit were consid-
ered to be 0 pg/ml. Absorbance was read in an ELISA
reader (Micro-Quant, Bio-Tek Instruments, Colmar,
France) at 490 and 540 nm as per manufacturer’s
instructions.
Quantitative real-time polymerase chain reaction
Calvariae were removed from culture medium, and
immediately snap-frozen in liquid nitrogen, and pulver-
ized to powder in a stainless steel mortar. RNA was
extracted with 1 mL Trizol® reagent (Invitrogen, Carls-
bad, CA, USA), using the manufacturer’s protocol.
Quantity and purity of RNA was determined by absor-
bance on a NanoDrop™ 1000 Spectrophotometer (Lab-
tech France, Palaiseau, France) at 260 and 280 nm. All
samples had ratios >1.7 and were accepted for analysis.
Samples of total RNA were reverse-transcribed using
the first-strand synthesis kit of SuperScript™ II Reverse
Transcriptase (Invitrogen). Quantitative gene expression
analyses were carried out using Real-time PCR by
means of the TaqMan™ Gene Expression Assays Proto-
col (mouse RANK: Mm00437135_m1, mouse RANKL:
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Mm01313943_m1, mouse OPG: Mm01205928_m1, and
human 18S rRNA: Hs99999901_s1; Applied Biosystems,
Foster City, CA, USA) and the iCycler thermal cycler
RT-PCR Detection System, coupled to MyiQ™ Single-
Color software (Bio-Rad, Hercules, CA, USA). The abso-
lute number of gene copies was normalized using 18s
rRNA and the relative quantification of the genes was
calculated using the “comparative CT (threshold cycle)
method” as per manufacturer’s instructions (Applied
Biosystems).
Data analysis
All values are presented as means ± SEM. Quantitative
parameters obtained from micro-CT (BV and Tb.Th)
were analyzed by two-tailed Student’s t-test within each
group. Comparisons across unpaired groups were made
according to the Mann-Whitney U test. Data concerning
osteoclast number, sagittal suture area, and bone thick-
ness were initially analyzed using a one-way analysis of
variance (ANOVA). Post hoc comparison between
groups used the Fisher’s protected least significant dif-
ference. Two-way ANOVA was performed to determine
whether there was a significant effect of either polyethy-
lene particles or ovariectomy or oestrogen supplementa-
tion on osteoclast number, sagittal suture area and bone
thickness. Cytokines concentrations and mRNAs expres-
sion were analyzed using one-way ANOVA followed by
the Bonferroni/Dunnet’s test. The level of statistical sig-
nificance was set at P < 0.05.
Results
Changes after OVX
All mice had increased body-weight by the end of the
experiment. The final body-weight gain was +18% in the
OVX group as compared to +6.8% (P < 0.0001), +3.5%
(P < 0.0001), and +11% (P = 0.0001) in normal controls,
sham-OVX mice, and OVX+E mice, respectively.
At sacrifice, atrophy of uterine tissue was noted, indi-
cating the effectiveness of oestrogen privation following
ovariectomy. There was a significant difference in uter-
ine weight in OVX mice group (mean, 24.5 ± 3.6 mg),
as compared to normal control animals (mean, 107.9 ±
12 mg, P < 0.0001), sham-OVX mice (mean, 86.4 ± 17
mg, P < 0.0001) and OVX+E mice (mean, 80.2 ± 10.9
mg, P < 0.0001). In contrast, uterine weight was notably
less altered after oestrogen supplementation in OVX
animals as compared to normal controls (80.2 ± 10.9
mg versus 107.9 ± 12 mg, P = 0.002).
Micro-CT evaluation of osteolysis
Ovariectomy induced a consistent, although non-signifi-
cant, decrease in mean grey-level intensity in calvariae
without PE particles as compared to normal controls
(Figure 1). Specifically, mean grey-level values were
117.6 ± 7.7 (range, 107 to 48), 115 ± 2 (range, 107 to
120) and 110 ± 0.3 (range, 109 to 111), in normal con-
trols, sham-OVX mice and OVX mice, respectively. In
contrast, grey-level intensity significantly increased in
OVX animals after oestrogen supplementation (124 ±
7.8), as compared to OVX mice (P = 0.02), while it was
similar to normal controls ({ P = 0.22) and sham-OVX
mice (P = 0.07). The presence of PE particles induced
profound changes in calvarial bone microarchitecture in
all groups (Figure 2). In particle-implanted animals, BV
significantly decreased within the VOI as compared to
sham-implanted animals in normal control group (P =
0.004), in sham-OVX group (P = 0.003), in OVX group
(P = 0.04) and in OVX+E group (P = 0.001) (Figure 3).
However, decrease in BV following particle implantation
was consistently less marked in the OVX group (-7.8%,
as compared to -21.2% in normal control group, P =
0.04, to -19.9% in sham-OVX group, P = 0.003, and to
-21.4% in OVX+E group, P = 0.005). Polyethylene parti-
cles did not produce any significant decrease in bone
thickness (Tb.Th) in OVX mice (+3.8% as compared to
sham-implanted OVX mice, P = 0.08), in contrast with
normal controls (-13.6% as compared to sham-
implanted normal controls, P = 0.01), sham-OVX mice
(-11.1% as compared to sham-implanted sham-OVX
mice, P = 0.008), and OVX+E group (-11.6% as com-
pared to sham-implanted OVX+E mice, P = 0.005) (Fig-
ure 4).
Figure 1 Grey-level intensity in entire calvariae, as assessed by
3D micro-CT. In the absence of PE particles, mean grey-level values
decreased in ovariectomized (OVX) mice as compared to normal
controls (NC) and Sham-OVX mice. Of note is the significant
increase of grey-level intensity in calvarial bone tissue of OVX
animals supplemented with oestrogen (E), as compared to OVX
mice. Grey-level values were obtained using CTAn software. The
data are presented as means ± standard error of the mean (a
indicates P < 0.05, as compared to OVX mice, using the Mann-
Whitney U test).
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Histology
Histological sections showed a consistent erosion of the
calvarial bone, associated to fibrous and granulomatous
scar tissue layer on the periosteal side of the calvaria in
particle-implanted mice, in all groups. The most dra-
matic lesions were observed when PE particles were
implanted in the OVX+E group (Figure 5). However,
the tissue response to particles appeared limited in OVX
animals without E supplementation. Using polarized
light, many particles were found intracellularly within
macrophages and foreign-body giant cells. TRAP
staining confirmed the presence of osteoclasts located in
resorptive lacunae.
Histomorphometric data are shown in Table 2. One-
way ANOVA revealed a significant difference for the
sagittal suture area (P < 0.0001). The presence of PE
particles induced a significant increase in SSA in normal
control group (P < 0.001), in sham-OVX group (P <
0.001), in OVX group (P < 0.001), and in OVX+E group
Figure 2 Effect of polyethylene particles on calvariae, as
assessed by longitudinal 3D micro-CT. Representative
reconstructed images of the calvarial volume of interest (VOI), two
weeks after sham-implantation (PE(-)) or PE particles implantation
(PE(+)) in different mice groups are shown (n = 7 per group). Of
note is the consistent extent of bone resorption area following
particles implantation in normal controls (NC), sham ovariectomized
(OVX) mice and OVX animals supplemented with oestrogen (E),
while bone resorption area appears limited in OVX animals
implanted with particles.
Figure 3 Effect of polyethylene particles on bone volume (BV),
as assessed by longitudinal 3D micro-CT. Bone volume
consistently decreased in all mice groups. However, bone loss was
significantly lower in ovariectomized (OVX) mice as compared to
normal controls (NC), sham-OVX mice and OVX animals
supplemented with oestrogen (E). Bone volume was quantified
using CTAn software. The data are presented as means ± standard
error of the mean (a indicates P < 0.005; b indicates P < 0.05,
compared to internal control, using Student’s t-test).
Figure 4 Effect of polyethylene particles on trabecular
thickness (Tb.Th), as assessed by longitudinal 3D micro-CT.
Trabecular thickness was not altered by the presence of particles in
ovariectomized (OVX) mice, as opposed to the other mice groups.
Trabecular thickness was quantified using CTAn software. The data
are presented as means ± standard error of the mean (a indicates P
< 0.005; b indicates P < 0.05, compared to internal control, using
Student’s t-test).
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Figure 5 Effect of polyethylene particles on calvariae, as assessed by histology. Representative stained calvarial histology (Stevenel Blue,
picrofuschine) is presented at ×20 original magnification (n = 7 per group). Polyethylene particles induced osteolysis, characterized by a
consistent decrease in calvarial bone thickness and an inflammatory response (arrowheads) in normal controls (NC), sham-ovariectomized (OVX)
mice and OVX mice supplemented with oestrogen (E), while it was moderate in OVX mice. PE(-): sham-implanted; PE(+): PE-implanted.
Table 2 Histomorphometric results for each mice group
Normal control group Sham-OVX group OVX group
OVX + Vehicle OVX+E
PE (-) PE (+) PE (-) PE (+) PE (-) PE (+) PE (-) PE (+)
SSA (mm2) 0.036 ± 0.008
(0.008 to .076)
0.10 ± 0.04
(0.05 to 0.33)
0.034 ± 0.007
(0.008 to 0.07)
0.093 ± 0.03
(0.05 to 0.34)
0.026 ± 0.01
(0.006 to 0.1)
0.09 ± 0.04
(0.01 to 0.35)
0.038 ± 0.01
(0.01 to 0.11)
0.20 ± 0.05
(0.07 to 0.46)
BT/TT 60 ± 4.7%
(42% to 80%)
48 ± 5.3%
(23% to 73%)
62 ± 4.6%
(49% to 80%)
45 ± 4%
(23% to 56%)
55 ± 5.2%
(35% to 73%)
49 ± 4.9%
(26% to 65%)
54 ± 5.5%
(31% to 73%)
37 ± 5.1%
(17% to 55%)
Δ(BT/TT) -12 ± 5.3%
(-37% to 12%)
-16 ± 4.5%
(-39% to 5%)
-6.7 ± 4.9%
(-30% to 9%)
-17 ± 5%
(-37% to 1.2%)
Oc Nb 0.31 ± 0.3
(0 to 2)
2.2 ± 0.7
(0 to 5)
0.42 ± 0.3
(0 to 2)
2.5 ± 0.7
(0 to 5)
0.65 ± 0.4
(0 to 3)
0.7 ± 0.5
(0 to 4)
0.27 ± 0.2
(0 to 1)
2.1 ± 0.8
(0 to 6)
Values are expressed as mean ± standard error of the mean (extremes). BT, bone thickness; E, oestrogen; Oc Nb, osteoclast number; OVX, ovariectomy; PE,
polyethylene; PE(-), sham-implanted; PE(+), PE-implanted; SSA, sagittal suture area; TT, tissue thickness.
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(P < 0.0001). No significant difference was found in SSA
between sham-implanted normal controls group and
sham-implanted OVX group (P = 0.9), between PE-
implanted normal control mice and PE-implanted OVX
mice (P = 0.99), and between sham-implanted normal
control mice and sham-implanted OVX+E mice (P = 1).
Two-way ANOVA revealed a significant effect of PE
particles on SSA (P < 0.0001). There was no indepen-
dent effect of OVX on SSA (P = 1) in the absence of
particles. One-way ANOVA revealed a significant differ-
ence for osteoclast number (P < 0.0001). The presence
of PE particles induced a consistent increase in osteo-
clast number in normal control group (P < 0.0001), in
sham-OVX group (P < 0.001), and in OVX+E group (P
< 0.0001), but not in OVX group (P = 0.99). There was
also a significant effect of ovariectomy on osteoclast
number (P = 0.047) in the absence of particles.
One-way ANOVA showed a significant difference for
bone thickness (P < 0.0001). Implantation of PE parti-
cles resulted in a marked decrease in BT/TT in normal
control group (P = 0.001), in sham-OVX group (P <
0.001), and in OVX+E group (P < 0.0001). However, the
presence of PE particles did not influence BT/TT in
OVX group (P = 0.088). Also, two-way ANOVA showed
an independent effect of ovariectomy on BT/TT (P <
0.001) in the absence of particles.
Serum levels of IL-6
Serum levels of IL-6 significantly increased after PE par-
ticles implantation in all mice groups, as compared with
sham-implanted internal controls (P = 0.008 in normal
control group, P = 0.01 in sham-OVX mice, and P =
0.02 in OVX+E mice), except in OVX mice group (P =
0.57) (Figure 6). Ovariectomy did not significantly
increase serum IL-6 concentrations in the absence of
particle implantation (sham-implanted OVX group ver-
sus sham-implanted normal controls, P = 0.78, and
sham-implanted OVX+E group versus sham-implanted
normal control mice, P = 0.84).
Production of cytokines in organ culture
The presence of PE particles induced a significant
increase in IL-1 b concentration in all mice groups (Fig-
ure 7). However, particles implantation did not signifi-
cantly influence IL-6 media rates as compared to
internal controls (Figure 7). In OVX mice without parti-
cles, the levels of TNF-a were significantly lower than
in normal controls (P = 0.02). In addition, in this group,
PE particles did not increase the rates of TNF-a (P = 1),
which remained considerably lower than in normal con-
trols and in OVX+E mice with PE particles (P = 0.002
and P = 0.002, respectively) (Figure 7). Significant differ-
ences in RANKL basal release (absence of particles
implantation) were found between OVX mice and each
other mice groups (normal controls, P = 0.047, sham-
OVX mice, P = 0.016, OVX+E mice, P = 0.02). Note-
worthy, RANKL local production appeared to be stimu-
lated by PE particles in normal controls, in sham-OVX
mice, and in OVX+E mice, while in OVX group, no sig-
nificant modification in RANKL rates could be detected
following particles implantation (P = 0.95) (Figure 7).
Quantitation of RANKL and OPG mRNA expressions in
calvariae
As shown in Figure 8, the combined effect of ovariect-
omy and PE particles implantation stimulated RANKL
mRNA expression in calvariae, in all mice groups. How-
ever, PE-implanted calvariae in normal controls, sham-
OVX and OVX+E mice expressed RANKL mRNA at
levels more than twice higher than OVX mice. OPG
mRNA expression was not significantly different
between groups (Figure 8). As a result, the RANKL/
OPG mRNA ratio significantly increased in all mice
groups after PE implantation, but appeared consistently
downregulated in OVX mice (Figure 8). The RANKL/
OPG mRNA ratio significantly differed between OVX
mice and each other mice group in the absence of parti-
cles (P = 0.047 as compared to normal controls, P =
0.034 as compared to sham-OVX mice, and P = 0.049
as compared to OVX+E mice). In addition, no signifi-
cant difference could be observed in the basal RANKL/
OPG mRNA ratio between normal controls and OVX+E
mice, indicating that E supplementation reestablished
RANKL mRNA expression relative to OPG mRNA.
Discussion
In a recent work [6], we have shown that experimental
stimulation of bone turnover by OVX resulted in a
Figure 6 Effect of polyethylene particles on serum levels of IL-
6 in each mice group. Blood was obtained by cardiac puncture 14
days after surgery (n = 5 per group). Serum levels of IL-6 were
determined by ELISA. Results are presented as mean ± standard
error of the mean (a indicates P < 0.01; b indicates P = 0.01; c
indicates P < 0.005, compared to internal control).
Nich et al. Arthritis Research & Therapy 2011, 13:R100
http://arthritis-research.com/content/13/3/R100
Page 7 of 12
paradoxical decrease in particle-induced osteolysis in the
murine calvaria model. To test the hypothesis that oes-
trogen-deficiency induced by OVX modulated the bone
response to particulate debris, we supplemented PE par-
ticle-implanted OVX mice with 17b-estradiol. Then, we
evaluated osteolysis and the involvement of the pro-
inflammatory cytokines IL-6, IL-1b, TNF-a, and
RANKL.
Our experiments show that the presence of PE parti-
cles induced an osteolytic reaction in bone calvaria in
normal controls, in sham-OVX mice and in OVX+E
mice, as illustrated by an extensive bone resorption and
an intense inflammatory reaction involving both bone
and periosteal tissue. In contrast, this process was con-
siderably attenuated in OVX mice, with almost no mod-
ification in trabecular thickness, osteoclast number and
periosteum thickness following PE implantation. In
addition, Bone volume appeared consistently less altered
following particles implantation, as compared to normal
controls and OVX mice supplemented with oestrogen.
Taken together, these data suggest that oestrogen defi-
ciency influenced positively bone response to particulate
debris. This finding appears paradoxical as clinical trials
[14-16] and experimental studies [17,18] have
demonstrated the protective effects of oestrogen against
inflammatory processes, such as rheumatoid arthritis
(RA). However, the relationship between oestrogen and
inflammation is controversial and might be related to a
different response of bone and inflammation cells.
Although it is admitted that oestrogen provides a pro-
tection against inflammation, it is also known that
female patients are more prone to develop inflammatory
diseases such as RA [19]. This point illustrates the dual
action of oestrogen, both anti- and pro-inflammatory.
Numerous cellular and molecular mechanisms leading
to bone resorption are common to osteolysis and oes-
trogen deficiency pathways. Cytokines such as IL-1, IL6,
TNF-a, and RANKL are up-regulated in both bone-
resorptive situations [20-24]. Differentiation of RANKL-
primed osteoclasts precursors, activation of mature
osteoclasts, and osteoclasts survival are enhanced by
TNF-a [25]. Zhang et al. [26] showed that TNF-a and
RANKL act synergistically on osteoclastogenesis in vitro.
The role of TNF-a in OVX-induced bone loss is well
documented [20,27,28]. Collectively, these studies sug-
gest that up-regulation of TNF-producing cells in the
bone marrow is a mechanism by which oestrogen defi-
ciency induces bone loss. Indeed, functional blockade of
Figure 7 Effect of polyethylene particles on the local expression of IL-1 b, IL-6, TNF-a and RANKL (ELISA). Cytokines concentrations were
determined after 24 hours in culture medium by ELISA (n = 5 per group). Results are presented as mean ± standard error of the mean. a
indicates P < 0.05, b indicates P < 0.005, c indicates P = 0.001, compared to internal control. IL-1 b, interleukin 1 b; IL-6, interleukin-6; TNF-a,
tumor necrosis factor-a; RANKL, receptor activator of the nuclear factor B ligand.
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TNF-a in mice leads to protection from OVX-induced
bone loss [27]. Accordingly, we found that TNF-a local
production was consistently altered in oestrogen defi-
cient mice, suggesting its involvement in limited osteo-
clastogenesis in this group.
In our experiments, local release of pro-inflammatory
cytokines IL1- b and IL-6 appeared heterogeneous. On
one hand, we found that pro-inflammatory cytokine IL-
1 b was stimulated by PE particles in all groups. On the
other hand, IL-6 local rates were not increased in the
presence of PE particles in any group. Indeed, it has
been suggested that the involvement of pro cytokines in
vivo may be difficult to demonstrate due to compensa-
tory process [29], and to the delayed time course of
release after particle implantation. Conversely, serum
IL-6 was stimulated by PE implantation in normal con-
trols, sham-OVX and E-supplemented OVX mice,
whereas no significant change occurred in OVX mice.
This point correlated well with the degree of osteolytic
reaction combining bone resorption and periosteal
inflammatory granuloma. The role of IL-6 as a stimula-
tor of bone resorption in post-menopausal osteoporosis
is well-known [30]. IL-6 promotes bone resorption by
affecting osteoclast differentiation and activity [31]. Our
results are in line with clinical data showing that serum
levels of IL-6 were consistently increased in patients
with loosened hip prosthesis [32]. However, authors
failed to correlate serum levels of IL-6 and the volume
of osteolysis [33]. These discrepancies suggest that
serum cytokine levels may be influenced by various fac-
tors, such as cytokine release from other organs, and
cytokine clearance rates from the joint. Taken together
with our findings, we speculate that serum and local IL-
6 changes may be involved in the mechanism underlying
the reduction of particle-induced osteolysis observed in
OVX mice. Thus, the hormonal status appears as a key
factor influencing serum IL-6 levels to be considered in
further clinical studies.
We observed that the combination of two bone-
resorptive stimuli resulted in a down-regulation of local
pro-resorptive cytokines TNF-a and RANKL, in parallel
with a limitation of bone loss. The latter appeared as a
consequence of decreased osteoclast activity and/or
recruitment and/or accelerated apoptosis. We assume
this process is regulated by the RANK/RANKL/OPG
pathway, synergistically with TNF-a secretion, since
Figure 8 Effect of polyethylene particles on the expression of RANKL, RANK and OPG in bone calvariae. Quantitative real-time PCR
analysis were performed 24 hours after calvariae culture (n = 5 per group). For every sample, experiments were carried out in triplicate and
results are presented as mean ± standard error of the mean. a indicates P < 0.05, compared to sham-implanted internal controls. OPG,
osteoprotegerin; RANK, receptor activator of the nuclear factor B; RANKL, RANK ligand.
Nich et al. Arthritis Research & Therapy 2011, 13:R100
http://arthritis-research.com/content/13/3/R100
Page 9 of 12
RANKL is required for osteoclasts differentiation, survi-
val and activity [21]. Pro-resorptive cytokine production
could have been altered at the cellular level. Hence, par-
ticle-induced osteolysis and postmenopausal osteoporo-
sis represent pro-inflammatory states with increased
inflammatory cytokines and activated T cells [34]. Cyto-
kines produced or regulated by T cells can enhance
osteoclast formation by increasing the RANKL/OPG
ratio [35]. Oestrogen deficiency also increases the
RANKL/OPG ratio through increases in pro-inflamma-
tory effectors, including IL-1b, IL-6, IL-11, TNF-a, M-
CSF and PGE [36]. RANKL expression was observed in
osteoblasts/stromal cells and bone marrow in postmeno-
pausal women. The molecular basis of the mechanism
by which oestrogen deficiency induces accelerated osteo-
clastogenesis is not yet elucidated [37]. In mice, the
selective ablation of oestrogen receptor in mature osteo-
clasts mimicked an osteoporotic bone phenotype [24],
suggesting that oestrogen directly regulates the life span
of differentiated osteoclasts, independently of an inflam-
matory pathway.
We hypothesize that the paradoxical decrease in bone
response to PE particles in OVX mice could be driven
by an innate protective mechanism that ultimately atte-
nuated focal bone resorption. Hence, a tight control of
innate immunity is essential because a disproportionate
immune response may considerably compound morbid-
ity. Recent studies suggested the involvement of T cells
not only in pathogen clearance but also in regulating
adaptative and innate immunity [38]. Recently, Guarda
et al. [39] reported that excessive inflammation was sup-
pressed by effector and memory T cells, via the block-
ade of mature IL-1b secretion, suggesting a possible
mechanism for the control of excessive inflammatory
responses.
We recognize limitations may have affected our find-
ings. First, calvarial bone tissue considerably differs from
long bone tissue with respect to cells, matrix composi-
tion and mineralization. Osteoclasts activity has been
shown to be highly variable, depending on bone-site ori-
gin [40,41]. Specifically, it was reported that proteolytic
enzymes used for bone matrix digestion [40,42], expres-
sion of TRAP enzyme, and size of osteoclasts originated
from calvarial bone differed from those present in long
bones [41,43]. Additionally, van den Bos et al. [44]
reported that calvarial bone exhibited differences in
matrix composition compared to long bone, including
degree of mineralization, amounts of collagen, osteogly-
cin, and pigment epithelium derived factor. These data
together indicate a putative difference in bone resorp-
tion characteristics in calvaria. Although the murine cal-
varial model has been extensively used to evaluate
particle-induced osteolysis [4-6], the clinical relevance of
our data should be considered with caution. Second, the
osteolysis murine model does not fully reproduce the
loading conditions of a prosthetic implant subjected to
loosening. The consequences of OVX on mouse calvar-
ial bone have been poorly studied. However, our obser-
vations revealed that basal calvarial bone thickness was
significantly reduced in OVX mice, confirming previous
findings [10,45]. This is consistent with bone resorption
of the skull and subsequent parietal bone thinning
observed in postmenopausal osteoporotic women [46].
Therefore, the current experimental protocol likely
mimicked comparable cellular and biologic bone
responses in OVX mice that occur in the early postme-
nopausal period. In the present work, we did not evalu-
ate cytokines local rates in a time-dependant fashion
after particles implantation. Hence, pro-inflammatory
cytokines are known to be highly labile and, subse-
quently, their local and serum concentrations may vary
with time. However, we limited our experiments to the
time period preceding the onset of theoretical substan-
tial bone repair. Therefore, it is likely that our cytokines
and mRNA evaluations are compatible with bone cellu-
lar response tested in our model.
Conclusions
The present study analysed the consequences of oestro-
gen deprivation in a murine model of particle-induced
osteolysis. We demonstrated that oestrogen deficiency
significantly attenuated osteolytic response to PE parti-
cles. This phenomenon was associated with a down-reg-
ulation of pro-inflammatory and pro-resorptive
cytokines TNF-a and RANKL, together with an absence
of increase of serum IL-6. We favour the alternative that
the combination of two bone-resorptive phenomenon
altered cytokines production, possibly via the implica-
tion of the periosteum in this mice model.
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